GlassScriptPhysician profile
Raymond H Johnson
NPI 1982602694
$1,131.14
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,131.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.60 | 2019 | |
| Abbvie INC. | $165.27 | 2019 | |
| Amgen INC. | $137.37 | 2019 | |
| Novartis Pharmaceuticals Corporation | $135.47 | 2019 | |
| Vifor Pharma, INC. | $111.51 | 2019 | |
| Amarin Pharma, INC. | $53.41 | 2019 | |
| Astellas Pharma US INC | $50.18 | 2019 | |
| Janssen Pharmaceuticals, INC | $40.04 | 2019 | |
| Glaxosmithkline, LLC. | $23.97 | 2019 | |
| Pfizer INC. | $22.96 | 2019 | |
| Avanir Pharmaceuticals, INC. | $14.59 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.46 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.85 | 2019 | |
| Merck Sharp & Dohme LLC | $11.86 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.68 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.